Introduction
============

Mesenchymal stem cells (MSC) are present in virtually all tissues where they interact with tissue cells and, under conditions of inflammation, with immune cells. They have multipotent differentiation capacity, which allows them to differentiate in osteoblasts, adipocytes, chondrocytes, and other cell types and they have immunomodulatory capacity by sensing and controlling inflammation and modifying the proliferation and cytokine production of lymphocytes and myeloid-derived immune cells ([@B1]). MSC are relatively easy to isolate and expand in culture and therefore have prospect as a therapeutic tool in degenerative and autoimmune disease and in transplantation. Experimental pre-clinical and clinical studies with MSC are based on the isolation of MSC from bone marrow or adipose tissues and the expansion of MSC *in vitro*. Culture-expanded MSC can be administered via different routes, including via intramuscular injections, subcutaneously and via intravenous infusion. While it was originally anticipated that MSC could be used for replacement of dysfunctional cells via their capacity to differentiate into tissue cells ([@B2]), the current paradigm is that MSC support resident progenitor cells via paracrine mechanisms ([@B3], [@B4]). Even this idea may need refinement as recent studies suggest that MSC may not have a long lifespan after administration ([@B5], [@B6]). The reason why this may be the case is not clear. A rapid disappearance of MSC raises the question of how MSC therapy might work. It is possible that a small fraction of administered MSC escapes death and migrates to sites of injury and inflammation and that these MSC bring about the beneficial effects of MSC. Another possibility is that MSC are able to rapidly pass on their effect to other cells that subsequently mediate tissue repair or immunomodulation. Even the clean-up process of MSC itself may be a trigger for the therapeutic effects of MSC. In the present review, we discuss recent findings on the life and fate of tissue resident and administered MSC and try to link these findings with the regenerative and immunomodulatory effects of MSC.

Migration of MSC *in vitro*
===========================

It has been shown that MSC migrate in response to many chemotactic factors, like platelet-derived growth factor-AB (PDGF-AB), insulin-like growth factor-1 (IGF-1), the chemokines RANTES, macrophage-derived chemokine (MDC), and stromal-derived factor-1 (SDF-1) ([@B7]). Accordingly, MSC express the tyrosine kinase receptors for PDGF and IGF, as well as the RANTES and MDC receptors CCR2, CCR3, and CCR4, and the SDF-1 receptor CXCR4. Most chemokines are more effective on TNFα-primed cells, suggesting that the mobilization of MSC and their subsequent homing to injured tissues may depend on the systemic and local inflammatory state ([@B7]). Whereas culture-expanded MSC are widely used in clinical trials, it is not clear how cultivation and GMP manufacturing processes may influence the homing properties of MSC *in vivo*. However, it has been shown that cell culture duration and the degree of cell expansion has a clear impact on MSC morphology, differentiation, viability, and migratory properties ([@B8]). Furthermore, several groups have shown that freshly isolated MSC show superior homing ability compared to expanded MSC ([@B9], [@B10]) and that different MSC subtypes, like classical MSC and multipotent adult progenitor cells have different migration potential ([@B11]) in *in vitro* migration assays. This suggests that different MSC preparations show variation with regard to their homing receptor expression, and this may result in differences in their therapeutic effect. Culture conditions appear therefore a potent tool in modulating the effect of MSC administration.

MSC express a range of chemokine receptors, allowing them to specifically migrate towards chemokine gradients.

Migration of Endogenous MSC
===========================

The study of endogenous MSC migration *in vivo* is complex. MSC are located in the bone marrow, from where they may migrate to other sites via mechanisms potentially similar to those exploited by hematopoietic stem cells. However, MSC may be resident in peripheral blood, which would make the specific identification of migrating MSC difficult. The detection of MSC in the circulation is controversial. While some studies showed that cord blood and mobilized peripheral blood are enriched for MSC ([@B12]), others failed to detect MSC in the circulation ([@B13]), even after stem cell mobilization or in cord blood ([@B14]). MSC have been detected in peripheral blood in patients with hip bone fractures ([@B15]), but it can be questioned whether MSC are present in the blood of these patients via active recruitment or whether mechanical disruption of the bone tissue is responsible for this. A study in rat showed that hypoxia induced the mobilization of MSC in peripheral blood ([@B16]) and a murine study investigating the mobilization of fluorescent MSC injected in the bone marrow of non-fluorescent animals detected an increased number of fluorescent MSC in the blood after the induction of liver damage ([@B17]), suggesting that systemic signals trigger the release of MSC from the bone marrow.

The migration of endogenous MSC is controversial. Hard evidence for the migration of MSC via the bloodstream is sparse. As MSC are present in virtually all tissues, they may migrate within tissues to sites of injury or inflammation.

One of the difficulties detecting circulating MSC is that their immunophenotype is not necessarily the same as that of culture-expanded MSC. Several of the markers used for the identification of MSC have an adhesion function and their expression is therefore likely to be different on non-adherent MSC. Furthermore, although the first compartment to search for circulating cells is usually the blood stream, a recent report suggests that adipose tissue derived MSC may migrate via the lymphatic system ([@B18]). It was demonstrated that MSC can be released by adipose tissue or bone marrow in response to inflammation and that they accumulate in lymph nodes and blood vessels via CXCL12 (SDF-1)/CXCR4 dependent mechanisms (Figure [1](#F1){ref-type="fig"}A). Finally, one may wonder whether the recruitment of MSC from distant sites is required for the control of immune responses and initiation of repair in tissues as MSC are found locally in all tissues, from skin to brain ([@B13]). In case of injury, local MSC from tissue or blood vessels need to travel only short distances to get to sites of injury and thereby cut the blood stream route short (Figure [1](#F1){ref-type="fig"}B).

![**Two potential routes for recruitment of endogenous MSC after tissue injury**. **(A)** Cytokines, chemokines, and growth factors like SCF, G-CSF, and SDF-1 are released by the injured tissue, which may trigger recruitment of MSC from the bone marrow to sites of injury via the circulation. **(B)** Alternatively, MSC are recruited from within tissues to sites of injury via migration within the stroma or via micro-capillaries. SCF, stem cell factor; G-CSF, granulocyte-colony stimulating factor; SDF-1, stromal cell derived factor-1; BM, bone marrow.](fimmu-05-00148-g001){#F1}

Transplanted organs provide a unique opportunity for studying the migration of MSC, as MSC can be cultured from tissue biopsies and their donor or recipient origin determined by HLA typing. A study in heart transplant patients demonstrated that MSC present in transplanted hearts were all of donor origin ([@B19]). No MSC of recipient origin were found, even not many years after transplantation. Similar data were found in lung transplant patients ([@B20]). These data suggest that MSC do not migrate between tissues, not even under inflammatory conditions as found in transplanted organs. At the same time these data demonstrate that MSC can in principle survive after transplantation. A major difference, however, between these studies and studies that show that **MSC are short-lived after administration** ([@B5]) as discussed in the next paragraph, is that MSC that are administered as a form of therapy are culture-expanded and administered without supporting tissue around them, as is the case in organ transplantation. The localization and microenvironment that MSC face after transplantation as a cell suspension or embedded in an organ are not comparable and are likely to be responsible for the apparent discrepant survival data.

*In vitro* expanded MSC have a short lifetime after *in vivo* administration. Intravenously infused MSC home to the lungs, from where they disappear within 24h. Living MSC are not detected at other tissue sites.

Localization and Homing of Exogenous MSC
========================================

The use of MSC for immunomodulation or regenerative therapy in pre-clinical models for autoimmune disease, transplantation, or degenerative disease offers the possibility of studying the migration of exogenous MSC. Several studies have demonstrated the homing of administered MSC to sites of injury ([@B21]--[@B23]). The migration of MSC to such sites may be dependent on chemotactic signals derived from injured or inflamed tissues. A study using a model of acute kidney injury demonstrated that the migration of MSC to the injured kidney is dependent on CD44 expression on MSC ([@B24]). The expression of the chemokine receptor CXCR4 on MSC also appears to play a role, as overexpression of CXCR4 increases the homing of MSC to injured kidneys ([@B25]).

The migration of MSC is likely to depend on their route of administration. Most studies use the intravenous route and it has become clear that a large proportion of MSC that are injected via this route are trapped in the lungs upon first passage ([@B5], [@B10], [@B23], [@B26]). After 24 h MSC are relocated to other organs, in particular the liver and also the spleen ([@B5], [@B27]). MSC also reappear at injured tissue sites ([@B27]). It is however questionable whether MSC that leave the lungs are still viable. In our previous work, we demonstrated that MSC are no longer viable 24 h after intravenous infusion, but that their radioactive label was still detectable in the liver ([@B5]). The elimination of MSC may be dependent of immunological mechanisms, which will be discussed below. The potential rapid disappearance of infused MSC does not rule out a functional effect of the cells. It has for instance been demonstrated that the phagocytosis of dead MSC induces the generation of macrophages with a regulatory phenotype ([@B28]) (Figure [2](#F2){ref-type="fig"}). It is also possible that a small proportion of cells escapes elimination and is responsible for the therapeutic effects of MSC.

![**Proposed mechanism of action of intravenously injected cultured MSC**. Administered culture-expanded MSC (large violet cells) target immune cells, including macrophages, and resident progenitor cells, including MSC (small red cells) via their secretome (e.g., TGF-β, PGE-2, and other factors) to stimulate immunomodulatory and regenerative processes. In addition, phagocytosis of MSC by macrophages may induce the formation of regulatory macrophages. TGF-β, transforming growth factor-β; PGE-2, prostaglandin E2.](fimmu-05-00148-g002){#F2}

Evasion of the lung trap may improve the survival of MSC and may affect the distribution of the cells after administration. Arterial injection may ensure better delivery of MSC to organs of interest. MSC injected in the renal arteries are retained in the glomeruli for at least several days ([@B29]). A study examining the engraftment of MSC in the liver concluded that administration via the portal vein led to far better engraftment than administration via the vena cava ([@B30]). While intravenous infusion of MSC for treatment of cardiac infarct has been shown long time ago to lead to poor engraftment in the ischemic heart, injection of MSC directly in the myocardium improves the uptake of cells ([@B26], [@B31]).

It thus appears that MSC are trapped in the first micro capillary network they encounter. The question is why this is the case and whether the entrapment of MSC in such networks perhaps contributes to in particular the immunomodulatory effects of MSC treatment?

Effect of Culture on the Migration and Survival of MSC
======================================================

Mesenchymal stem cells cultures are routinely obtained by adherence of MSC to plastic culture flasks and propagation of the cells in medium containing 10--15% fetal calf serum ([@B32]). However, **culture affects the phenotype of MSC**. Various studies show that surface markers of freshly isolated MSC differ from those of cultured MSCs. It has for instance been described that adipose tissue derived MSC are contained in the CD34^+^ cell fraction of the stromal vascular fraction, but CD34 expression is lost during MSC cell expansion in culture ([@B33]). Recently, Braun et al. ([@B34]) showed that upon activation in culture, MSC upregulate CD105, CD146, and CD271 and propose that this upregulation is required for improved motility and attachment to the plastic. In accordance with this hypothesis, we as well as other groups have observed a change in MSC morphology during early culture phase. Over time, small round-shaped cells change into large spindle shaped cells ([@B34], [@B35]) and cultured MSC become around 20 μm in diameter ([@B36], [@B37]). Since this diameter is larger than the size of pulmonary micro-capillaries, it is not surprising that after intravenous infusion of MSC the majority of the cells are trapped in the lungs ([@B5], [@B37]). Furthermore, the modulated expression of cell adhesion and chemoattraction molecules on cultured MSC may account for a different migratory behavior of cultured MSC compared to non-cultured MSC. The shortevity of MSC after infusion may also have a relation with the culture-induced changes in MSC phenotype. We and others have demonstrated that activated NK cells can lyse culture-expanded MSC of not only allogeneic but also autologous origin ([@B38], [@B39]), suggesting that culture may induce changes in MSC that makes them targets for NK cells. Cultured MSC may also appear foreign for macrophages, and trigger a clean-up response after administration, which may result in an immunosuppressive effect as discussed above ([@B28]). These data indicate that it is not unlikely that at least some of the effects observed upon administration of MSC depend on MSC properties acquired during culture expansion.

Culture medium and plastic adherence have a major impact on the phenotype of MSC. The size of MSC dramatically increases in culture and the expression of adhesion molecules is strongly up regulated. This affects the distribution of MSC after administration.

How Does MSC Therapy Work?
==========================

Series of observations on the migration, distribution, and survival of MSC after administration contrast with the original ideas on the life and fate of MSC and make it hard to understand how MSC therapy works. In the 1960s, cells with osteogenic differentiation capacity were identified in the bone marrow by Friedenstein and colleagues ([@B40]). Later it was shown that in addition to osteogenic differentiation, these cells, MSC, were able to undergo adipogenic, chondrogenic, and myogenic differentiation ([@B41]). As a logic consequence it was believed that MSC could be expanded in culture, administered and that they would engraft and differentiate into functional cells. Some of the early trials with MSC that took place in osteogenesis imperfecta patients were based on this idea ([@B42]). It turned out, however, that culture-expanded MSC show little engraftment and it is proposed that the secretion of trophic factors and immunomodulatory cytokines and chemokines by MSC are at the base of the therapeutic effects ([@B43], [@B44]). However, the accumulation of MSC in the lungs after intravenous infusion, their short survival time and limited distribution to other sites suggests that MSC rapidly pass on their effect to resident cells, which may subsequently mediate the immunomodulatory and regenerative effect induced by MSC administration. This idea is summarized in Figure [3](#F3){ref-type="fig"}.

![**Proposed model of MSC contribution to immune suppression and tissue repair**. Intravenous administration of culture-expanded MSC (violet cells) leads to modulation of the function of endogenous MSC (red cells) and macrophages via the secretome of the administered cells (e.g., TGF-β, PGE-2, and other factors) and phagocytosis of MSC by macrophages. The activation of resident MSC and induction of regulatory macrophages induces tissue regeneration. MSC furthermore induce regulatory T cells via different mechanisms, including the secretion of TGF-β and an indirect elevation of IL2. Administration of MSC also elicits a systemic immune response, which triggers an immunosuppressive response.](fimmu-05-00148-g003){#F3}

Regulatory T cells are one of the cell types that may bring the effects of MSC forward. MSC have been demonstrated to be able to induce regulatory T cells ([@B45], [@B46]). The mechanisms of MSC-induced regulatory T cell induction depend on local conditions. MSC constitutively secrete TGF-β, which acts as a growth factor for regulatory T cells ([@B45]), and under inflammatory conditions MSC express IDO, which plays a role in the generation of regulatory T cells ([@B47]). MSC induce *de novo* regulatory T cells by increasing levels of IL2, which occurs when activated T cells are inhibited by MSC in their proliferation but not in their activation ([@B46]). Furthermore, monocytes are identified as a crucial intermediate cell type after MSC-induced differentiation in type 2 macrophages. Type 2 macrophages produce IL10 and CCL18, which trigger the induction of regulatory T cells. Type 2 macrophages can furthermore be induced by prostaglandin E2 secretion by MSC ([@B48]) and themselves play a role in resolving inflammation and mediating tissue repair ([@B49]). It was recently demonstrated that the reparative effect of MSC injected in infarcted myocardium was partially mediated via type 2 macrophages as depletion of these macrophages attenuated the MSC effect ([@B50]).

As infused MSC are around only for a short time, their induction of cells with regulatory phenotypes via the secretion of soluble factors has to occur hastily. It is also possible that MSC trigger responses by other cells merely by their presence. We recently demonstrated that **MSC induce a systemic inflammatory response** within hours after infusion ([@B51]). Whether this response triggers the induction of regulatory cells and whether it originates from MSC or from resident tissue and/or immune cells remains to be identified. It however indicates that infusion of MSC leads to rapid responses that may subsequently affect other cells. The systemic nature of the response indicates that even though MSC are localized in the lungs after infusion, their effects can reach other body sites, and this may underlie the **mechanism of MSC therapy**. What happens to MSC after they disappear from the lungs is not clear. It may be that small numbers of MSC escape elimination and migrate to sites of injury, but whether these surviving MSC mediate the therapeutic effect or whether the bulk dead cells are responsible for this we cannot conclude about at this moment. There is evidence that dead MSC reappear in the liver ([@B5]), and interestingly, macrophages that phagocytized dead MSC have been shown to obtain a regulatory function ([@B28]).

MSC induce an inflammatory response after infusion, which is detectable in lung tissue and systemically 2h after administration. This response may lead to the immunomodulatory effects seen after MSC infusion.

The mechanisms of MSC therapy are poorly understood. As MSC have a short survival time after infusion, it is believed that MSC pass on their effects to other cell types. MSC can induce regulatory T cells and regulatory macrophages, which carry on the immunomodulatory and regenerative effects of MSC.

Taking all published data into considering, we have to acknowledge that we yet know little about how MSC therapy works. Further studies aimed at exploring MSC fate and functional properties after administration will have to shine light on this and allow the design of effective MSC therapy.
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